BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hager S, Fittler FJ, Wagner E, Bros M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells 2020;9:E2061. [PMID: 32917034 DOI: 10.3390/cells9092061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Chen S, Zhang J, Ye Q, Liu Y. DNA Nano Trihedron Exhibits an Inhibitory Effect on Breast Cancer Cells. ACS Omega 2023. [DOI: 10.1021/acsomega.2c07859] [Reference Citation Analysis]
2 He Y, Li D, Wu L, Yin X, Zhang X, Patterson LH, Zhang J. Metal‐Organic Frameworks for Gene Therapy and Detection. Adv Funct Materials 2023. [DOI: 10.1002/adfm.202212277] [Reference Citation Analysis]
3 Hoffmann M, Gerlach S, Hoffmann C, Richter N, Hersch N, Csiszár A, Merkel R, Hoffmann B. PEGylation and folic-acid functionalization of cationic lipoplexes-Improved nucleic acid transfer into cancer cells. Front Bioeng Biotechnol 2022;10:1066887. [PMID: 36619382 DOI: 10.3389/fbioe.2022.1066887] [Reference Citation Analysis]
4 Wu Y, Zhang Z, Wei Y, Qian Z, Wei X. Nanovaccines for cancer immunotherapy: Current knowledge and future perspectives. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.108098] [Reference Citation Analysis]
5 Eljack S, Allard-Vannier E, Misericordia Y, Hervé-Aubert K, Aubrey N, Chourpa I, Faggad A, David S. Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells. Pharmaceutics 2022;14. [PMID: 36432729 DOI: 10.3390/pharmaceutics14112537] [Reference Citation Analysis]
6 Wang Q, Wang Z, Sun X, Jiang Q, Sun B, He Z, Zhang S, Luo C, Sun J. Lymph node-targeting nanovaccines for cancer immunotherapy. J Control Release 2022;351:102-22. [PMID: 36115556 DOI: 10.1016/j.jconrel.2022.09.015] [Reference Citation Analysis]
7 Shah P, Lalan M, Barve K. Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders. Front Pharmacol 2022;13:974666. [DOI: 10.3389/fphar.2022.974666] [Reference Citation Analysis]
8 Chavda VP, Patel AB, Vora LK, Apostolopoulos V, Uhal BD. Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management. Expert Rev Vaccines 2022. [PMID: 35929957 DOI: 10.1080/14760584.2022.2110076] [Reference Citation Analysis]
9 Nie W, Chen J, Wang B, Gao X. Nonviral vector system for cancer immunogene therapy. MedComm – Biomaterials and Applications 2022;1:mba2.10. [DOI: 10.1002/mba2.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang Z, Liu X, Zhao F, Yao M, Lin Z, Yang Z, Liu C, Liu Y, Chen X, Du C. Bioactive glass nanoparticles inhibit osteoclast differentiation and osteoporotic bone loss by activating lncRNA NRON expression in the extracellular vesicles derived from bone marrow mesenchymal stem cells. Biomaterials 2022;283:121438. [DOI: 10.1016/j.biomaterials.2022.121438] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Berger S, Berger M, Bantz C, Maskos M, Wagner E. Performance of nanoparticles for biomedical applications: The in vitro / in vivo discrepancy. Biophysics Rev 2022;3:011303. [DOI: 10.1063/5.0073494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Shahcheraghi N, Golchin H, Sadri Z, Tabari Y, Borhanifar F, Makani S. Nano-biotechnology, an applicable approach for sustainable future. 3 Biotech 2022;12:65. [PMID: 35186662 DOI: 10.1007/s13205-021-03108-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Ye Z, Abdelmoaty MM, Curran SM, Dyavar SR, Kumar D, Alnouti Y, Coulter DW, Podany AT, Singh RK, Vetro JA. Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC. ncRNA 2022;8:8. [DOI: 10.3390/ncrna8010008] [Reference Citation Analysis]
14 Brohlin OR, Ehrman RN, Herbert FC, Wijesundara YH, Raja A, Shahrivarkevishahi A, Diwakara SD, Smaldone RA, Gassensmith JJ. Zeolitic Imidazolate Framework Nanoencapsulation of CpG for Stabilization and Enhancement of Immunoadjuvancy. ACS Appl Nano Mater . [DOI: 10.1021/acsanm.1c03555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 2022;7:e153688. [PMID: 35014625 DOI: 10.1172/jci.insight.153688] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Hosseini M, Baghaei K, Hajivalili M, Zali MR, Ebtekar M, Amani D. The anti-tumor effects of CT-26 derived exosomes enriched by MicroRNA-34a on murine model of colorectal cancer. Life Sci 2021;290:120234. [PMID: 34953890 DOI: 10.1016/j.lfs.2021.120234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Bishani A, Chernolovskaya EL. Activation of Innate Immunity by Therapeutic Nucleic Acids. Int J Mol Sci 2021;22:13360. [PMID: 34948156 DOI: 10.3390/ijms222413360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Tong PH, Zhu L, Zang Y, Li J, He XP, James TD. Metal-organic frameworks (MOFs) as host materials for the enhanced delivery of biomacromolecular therapeutics. Chem Commun (Camb) 2021;57:12098-110. [PMID: 34714306 DOI: 10.1039/d1cc05157a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
19 Prajapati R, Somoza Á. Albumin Nanostructures for Nucleic Acid Delivery in Cancer: Current Trend, Emerging Issues, and Possible Solutions. Cancers (Basel) 2021;13:3454. [PMID: 34298666 DOI: 10.3390/cancers13143454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Xiong H, Veedu RN, Diermeier SD. Recent Advances in Oligonucleotide Therapeutics in Oncology. Int J Mol Sci 2021;22:3295. [PMID: 33804856 DOI: 10.3390/ijms22073295] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 21.0] [Reference Citation Analysis]
21 Naik GG, Shah J, Balasubramaniam AK, Sahu AN. Applications of natural product-derived carbon dots in cancer biology. Nanomedicine (Lond) 2021;16:587-608. [PMID: 33660530 DOI: 10.2217/nnm-2020-0424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
22 Wan Z, Zheng R, Moharil P, Liu Y, Chen J, Sun R, Song X, Ao Q. Polymeric Micelles in Cancer Immunotherapy. Molecules 2021;26:1220. [PMID: 33668746 DOI: 10.3390/molecules26051220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Berger S, Krhač Levačić A, Hörterer E, Wilk U, Benli-Hoppe T, Wang Y, Öztürk Ö, Luo J, Wagner E. Optimizing pDNA Lipo-polyplexes: A Balancing Act between Stability and Cargo Release. Biomacromolecules 2021;22:1282-96. [PMID: 33616407 DOI: 10.1021/acs.biomac.0c01779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
24 Nowak I, Sarshad AA. Argonaute Proteins Take Center Stage in Cancers. Cancers (Basel) 2021;13:788. [PMID: 33668654 DOI: 10.3390/cancers13040788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ye Z, Abdelmoaty MM, Ambardekar VV, Curran SM, Dyavar SR, Arnold LL, Cohen SM, Kumar D, Alnouti Y, Coulter DW, Singh RK, Vetro JA. Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer. Nanomedicine 2021;33:102363. [PMID: 33545405 DOI: 10.1016/j.nano.2021.102363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]